Currently approved treatments for schizophrenia only minimally
affect the cognitive features of the illness that are the most closely
related to disability. Hence, there is now considerable effort to
repurpose drugs for schizophrenia, and to seek agents that can improve
cognition by targeting receptor systems other than the dopaminergic
system. The results of these studies have been mixed thus far; however,
this continues to be a high-priority area of schizophrenia research and
an important unmet need.
Leave a comment